EUCTR2013-004288-30-AT进行中（未招募）不适用
A Prospective, Single Center, Post-Market Observational Study to Assess the Efficacy, Safety, and Patient Reported Outcomes of Insulin Delivery with PaQ® in Patients with Type 2 Diabetes Mellitus.
CeQur Corp.0 个研究点开始时间: 2014年5月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Is at least 18 years of age;
- •2.Has a clinical diagnosis of T2DM, as determined by clinical history and medication usage;
- •3.Has an A1C = 7.0% and = 11.0%;
- •4.Is treated with basal-bolus insulin therapy (at least 2 injections per day) with or without OADs, and/or GLP-1 agonist for at least 3 months and has not had a change (addition or discontinuation of existing drug or change in dose) in their OADs for the last 8 weeks, (See Section 7.4 for definition of baseline basal bolus therapy);
- •5.Determined by the investigator that insulin requirements to achieve glycemic targets can be met by the insulin capacity of the PaQ device;
- •6.If on concomitant metformin, has serum creatinine <1.5 mg/dL (male) or <1.4 mg/dL (female);
- •7.If female, and of child-bearing potential, has a negative urine pregnancy test at screening and must be using adequate means of contraception as determined by the Investigator;
- •8.Is clinically euthyroid as judged by the Investigator;
- •9.Is able to understand and sign the required study documents and comply with the CIP requirements;
- •10.Is deemed capable by the Investigator to perform the requirements of the CIP, including use of PaQ, frequent self-monitoring of blood glucose.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1.Is poorly compliant with the currently prescribed diabetes regimen, as determined by the Investigator;
- •2.Is poorly compliant with prescribed self-monitoring of blood glucose, as determined by the Investigator;
- •3.Is currently taking or has taken sulfonylureas within the last 2 months;
- •4.Has a BMI greater than 40 kg/m2;
- •5.Has experienced recurrent severe hypoglycemia (> 2 episodes) requiring assistance during the past 6 months;
- •6.Has existing dermal irritation/inflammation over the abdominal area that may interfere with use of PaQ, as determined by the Investigator;
- •7.Has known clinically significant hypersensitivity to skin adhesives;
- •8.Is female and if of child-bearing potential, is pregnant, lactating, or planning to become pregnant;
- •9.Is currently being treated with or expected to require or undergo treatment with systemic steroids by oral, intravenous, or intramuscular route (inhaled with low systemic exposure is permitted);
- •10.Currently abuses drugs or alcohol or has a history of abuse that in the Investigator’s opinion would cause the individual to be non-compliant;
- •11.Has received any investigational drug within 1 month;
- •12.Has donated blood within 30 days;
- •13.Has any significant medical condition (including current or past history of cardiovascular disease), laboratory findings, or medical history that in the Investigator’s opinion may affect successful completion of the study and/or personal well-being;
- •14.Is an immediate family member (spouse, parent, child, or sibling) of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site.
研究者
相似试验
尚未招募
4 期
To evaluate safety and performance of the Evermine 50-50μm Everolimus-Eluting Coronary Stent System (EES) in the treatment of patients with de novo native coronary artery lesions.CTRI/2017/03/008173Meril Life Sciences Pvt Ltd250
已完成
4 期
Clinical outcome and fusion rates after surgery with TM Ardis interbody fusion systemSpondylolisthesisISRCTN89404187Zimmer Spine (France)80
招募中
4 期
Evaluation of Effectiveness And Safety Of Clarithromycin In Upper Respiratory Tract InfectioCTRI/2024/06/069427Abbott Healthcare Private Limited
尚未招募
4 期
A clinical trial to assess the efficacy and safety of Formoterol fumarate and Fluticasone propionate powder for inhalation (Formoflo 250) in the patients withAsthmaCTRI/2023/08/056250upin Limited
已完成
4 期
A PROSPECTIVE MULTI-CENTRE, POST MARKETING SURVELLANCE (PMS) STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SLVRGEN IN PATIENTS WITH SUPERFICIAL PARTIAL-THICKNESS BURNS.CTRI/2014/01/004350Bharat Biotech International Limited500